Olaparib shows survival benefits in mCRPC and OC

Olaparib has demonstrated survival benefits in BRCA1/2-positive metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-positive ovarian cancer (OC), according to results of the PROfound trial and 5-year results of the SOLO1 trial presented at the European Society for Medical Oncology Virtual Congress 2020 (ESMO 2020).

New Molecule

7 New

New Formulation

1 New

New Indication

4 New

Color 1
Color 2
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in